Literature DB >> 12515742

Differential role of K(ATP) channels activated by conjugated estrogens in the regulation of myocardial and coronary protective effects.

Tsung-Ming Lee1, Tsai-Fwu Chou, Chang-Her Tsai.   

Abstract

BACKGROUND: We have demonstrated that estrogen can reduce myocardial injury in ischemia-reperfusion via activation of ATP-sensitive potassium (K(ATP)) channels. We sought to determine whether the protective effect of estrogen extends to epicardial coronary artery with attenuated vasoconstriction in patients after angioplasty by activation of such channels. METHODS AND
RESULTS: The study was designed to prospectively investigate 41 consecutive patients scheduled for elective coronary angioplasty. Pretreatment with estrogen limited myocardial ischemia during coronary occlusion and attenuated postangioplasty coronary vasoconstriction at the dilated and distal segments. An inhibitor of K(ATP) channels, glibenclamide, did not affect coronary vasomotor response, although it abolished the beneficial effect of estrogen on myocardial ischemia. Patients to whom estrogen was administered after the second balloon deflation experienced a similar magnitude of myocardial ischemia as controls but showed significantly attenuated vasoconstriction compared with controls (P=0.0001). Endothelin-1 levels from the great cardiac vein rose significantly from 1.9+/-0.4 to 3.1+/-0.6 pg/mL (P=0.001) 15 minutes after angioplasty in the control group; this was attenuated after estrogen was administered. Significant correlation was found between the changes in coronary vasomotion of the dilated segment and endothelin-1 levels (r=0.65, P<0.0001).
CONCLUSIONS: These results demonstrate that estrogen is protective against both myocardial ischemia and coronary vasoconstriction through different mechanisms. The myocardial effect of estrogen was abolished by glibenclamide, which suggests that the cardioprotective effect of estrogen may result from activation of K(ATP) channels. In contrast, estrogen-induced attenuated vasoconstriction is associated with an attenuated release of endothelin-1, independent of K(ATP) activation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12515742     DOI: 10.1161/01.cir.0000043243.49875.2e

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  6 in total

1.  Estrogenic Impact on Cardiac Ischemic/Reperfusion Injury.

Authors:  Sivaporn Sivasinprasasn; Krekwit Shinlapawittayatorn; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  J Cardiovasc Transl Res       Date:  2016-01-19       Impact factor: 4.132

2.  KMUP-3 attenuates ventricular remodelling after myocardial infarction through eNOS enhancement and restoration of MMP-9/TIMP-1 balance.

Authors:  Chung-Pin Liu; Jwu-Lai Yeh; Bin-Nan Wu; Chee-Yin Chai; Ing-Jun Chen; Wen-Ter Lai
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

3.  Augmented sympathetic vasoconstriction in exercising forearms of postmenopausal women is reversed by oestrogen therapy.

Authors:  Paul J Fadel; Zhongyun Wang; Hitoshi Watanabe; Debbie Arbique; Wanpen Vongpatanasin; Gail D Thomas
Journal:  J Physiol       Date:  2004-10-21       Impact factor: 5.182

Review 4.  Rapid estrogen actions on ion channels: A survey in search for mechanisms.

Authors:  Lee-Ming Kow; Donald W Pfaff
Journal:  Steroids       Date:  2016-03-03       Impact factor: 2.668

5.  Sexual dimorphism in vascular ATP-sensitive K+ channel function supporting interstitial P O 2 via convective and/or diffusive O2 transport.

Authors:  Trenton D Colburn; Ramona E Weber; Kiana M Schulze; K Sue Hageman; Andrew G Horn; Brad J Behnke; David C Poole; Timothy I Musch
Journal:  J Physiol       Date:  2021-06-08       Impact factor: 6.228

6.  Oestradiol: any role in cardiovascular risk factors in female centenarians of Hainan?

Authors:  Qiao Zhu; Yao Yao; Chao-Xue Ning; Xiao-Ping Chen; Fu-Xin Luan; Liang Liu; Qiong Liu; Na Wang; Fu Zhang; Ya-Li Zhao
Journal:  BMC Cardiovasc Disord       Date:  2019-05-16       Impact factor: 2.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.